Veru's Obesity Trial Fully Enrolled at 239 Patients, Key Patent Allowed
VERU is trading near its 52-week low of $2.05 (12% above the low) on light trading volume (0.1× avg).
Summary
Veru's Phase 2b PLATEAU trial for enobosarm combined with semaglutide in older obese patients has fully enrolled 239 patients, exceeding the 200-patient target. The company also received a USPTO notice of allowance for a key U.S. patent covering the combination, extending protection to at least 2044. These updates accompany fiscal Q3 results, though specific financial figures were not detailed in the release. The trial's interim analysis remains on track for Q1 2027, with final data expected in Q4 2027. This follows the June clinical supply agreement with Novo Nordisk for Wegovy, reinforcing the program's momentum.
At the time of this announcement, VERU was trading at $2.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.4M. The 52-week trading range was $2.05 to $7.33. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.